Indication
In combination with carboplatin and etoposide for the first‑line treatment of adult patients with extensive‑stage small cell lung cancer (ES‑SCLC).
Medicine details
- Medicine name:
- serplulimab (Hetronifly)
- SMC ID:
- SMC2840
- Pharmaceutical company
- Accord Healthcare
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Full
- Publication due date:
- 12 January 2026
- SMC meeting date:
- 02 December 2025
- Patient group submission deadline:
- 06 October 2025